NASDAQ:AVEO AVEO Pharmaceuticals (AVEO) Stock Price, News & Analysis → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free AVEO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$14.99▼$15.0050-Day Range$14.90▼$15.0052-Week Range$3.06▼$15.00Volume247,800 shsAverage Volume601,442 shsMarket Capitalization$521.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get AVEO Pharmaceuticals alerts: Email Address Ad Wealthpin ProOne trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. About AVEO Pharmaceuticals Stock (NASDAQ:AVEO)AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Read More Ad Wealthpin ProOne trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. AVEO Stock News HeadlinesApril 23, 2024 | msn.comVIDEO: How the Chevrolet Aveo Looks Like in Real-LifeApril 22, 2024 | msn.comWhat does the Chevrolet Aveo Have to offer? The Details You Need to Know if You Live in the United StatesApril 24, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? April 22, 2024 | msn.comFind Out What the New Chevrolet Aveo Interior Has to OfferMarch 28, 2024 | forbes.comKorean Conglomerate LG To Invest $74 Billion In AI, Biotech, Cleantech And Other Growth AreasMarch 28, 2024 | globenewswire.comCORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeMarch 25, 2024 | finanznachrichten.deAVEO Pharmaceuticals, Inc.: AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeMarch 25, 2024 | globenewswire.comAVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeApril 24, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? March 12, 2024 | finance.yahoo.comNeuroendocrine Tumor Treatment Market revenue to hit USD 8 Billion by 2035, says Research NesterMarch 6, 2024 | msn.com2024 Chevrolet Aveo: Driving The Compact Expat In Mexico CityNovember 30, 2023 | finance.yahoo.comAVEO Oncology, an LG Chem company, Earns Spot on Boston Globe's 2023 Top Places to Work List for Second Consecutive YearNovember 3, 2023 | finance.yahoo.comActinium Appoints Lynn Bodarky as Chief Business OfficerOctober 30, 2023 | afr.comBrookfield finalises $1.45b debt refi for Aveo; lenders pile inJuly 13, 2023 | afr.comBrookfield locks in $1.45b debt refi for Aveo; five banks underwriteMay 10, 2023 | finance.yahoo.comActinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals DayMay 5, 2023 | marketwatch.com2023 Kidney Cancer Market Size Growth Analysis by Absolute Reports | with [101 Pages] and Forecast till 2031May 3, 2023 | marketwatch.comC-MET & HGF Inhibitors Market Growth Opportunities and Emerging Trends till 2031May 3, 2023 | marketwatch.comFGF-2 Inhibitors Market 2023 SWOT Analysis and Demand Status Forecast by 2030April 27, 2023 | marketwatch.comC-MET / HGF Inhibitors Market Size [2023] Global Overview includes Market Trends and Forecast to 2027 | with [148 Pages]April 27, 2023 | marketwatch.comHepatocyte Growth Factor Market Research Analysis 2023-2031April 25, 2023 | marketwatch.comNeuroendocrine Tumors Treatment Market 2023 to 2030 Market Analysis, Share, Size, Trends, Scope, Growth Drivers, By Top Companies And ForecastApril 23, 2023 | marketwatch.com2023-2030 Kidney Cancer Treatment Drugs Market Share, Detailed Examination of Industry Trends and OpportunitiesApril 20, 2023 | marketwatch.comIndustry Research Report on C-MET / HGF Inhibitors Market Share and Industrial Overview till 2030April 16, 2023 | marketwatch.comC-MET / HGF Inhibitors Market Forecast to 2030April 14, 2023 | msn.com2024 Chevy Aveo: The Sonic Is Still Alive and Thriving, Just Not in the U.S.April 12, 2023 | marketwatch.comC-MET & HGF Inhibitors Market Growth by 2030See More Headlines Receive AVEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:AVEO CUSIP05358810 CIK1325879 Webwww.aveooncology.com Phone(617) 400-0101Fax617-995-4995Employees114Year Founded2001Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,340,000.00 Net Margins-30.79% Pretax Margin-30.79% Return on Equity-81.66% Return on Assets-28.83% Debt Debt-to-Equity Ratio0.94 Current Ratio2.37 Quick Ratio2.35 Sales & Book Value Annual Sales$42.29 million Price / Sales12.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book11.28Miscellaneous Outstanding Shares34,763,000Free Float33,619,000Market Cap$521.45 million OptionableOptionable Beta1.00 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMichael P. BaileyPresident, Chief Executive Officer & DirectorJebediah LedellChief Operating OfficerErick J. LuceraChief Financial OfficerMatthew CoulterVice President-Information TechnologyStefanie SolomonHead-ComplianceKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXXOMANASDAQ:XOMAVanda PharmaceuticalsNASDAQ:VNDAVerastemNASDAQ:VSTMMerrimack PharmaceuticalsNASDAQ:MACKView All Competitors AVEO Stock Analysis - Frequently Asked Questions How were AVEO Pharmaceuticals' earnings last quarter? AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The biopharmaceutical company earned $15.17 million during the quarter, compared to analysts' expectations of $14.29 million. AVEO Pharmaceuticals had a negative trailing twelve-month return on equity of 81.66% and a negative net margin of 30.79%. During the same quarter in the prior year, the firm earned ($0.33) earnings per share. When did AVEO Pharmaceuticals' stock split? AVEO Pharmaceuticals shares reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO? 4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend. What other stocks do shareholders of AVEO Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA). This page (NASDAQ:AVEO) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVEO Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
